Chugai Pharmaceutical reports 1H results
Seeking Alpha ·
Chugai Pharmaceutical press release ( CHGCF ): 1H EPS: ¥140.82, ¥144.84 Revenue: ¥663,300M Product sales: ¥566,500M Research & development expenses: ¥89,600M Selling, general and administrative expenses: ¥57,900M Other operating income (expenses): ¥900M Chugai Pharmaceutical Co., Ltd. 2026 Q2 - Results - Earnings Call Presentation Historical earnings data for Chugai Pharmaceutical Co., Ltd. Financial information for Chugai Pharmaceutical Co., Ltd.
AI 시장 분석
Chugai Pharmaceutical reported a Q1 earnings per share of 140.82 yen and revenue of 6633 billion yen. Product sales reached 5665 billion yen, while R&D expenses and SG&A expenses were recorded at 896 billion yen and 579 billion yen, respectively. This earnings report demonstrates the company's solid core business growth and suggests stable cash flow within the global pharmaceutical market. Investors should closely monitor the future pipeline development speed and cost efficiency.
상승 영향
- Biotechnology — Product sales reached 5665 billion yen, proving solid financial results and ensuring smooth R&D investments.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 52% · Bearish (Short) 48%
514 participants
Related News
- Flagstar Bank, National Association Non-GAAP EPS of $0.05 misses by $0.02, revenue of $516M misses by $26.69M
- Acerinox, S.A. reports Q2 results
- Better IPO Stock: Anthropic vs. OpenAI
- Stillfront Group AB (publ) reports Q2 results
- US stocks face tests from Fed decision, tech-led earnings deluge
- Amazon FTC settlement deadline is just days away. How to file claim
